9 / 17
Page 22
Virology research J 2017 Vol 1 Issue 2
Notes:
July 26-27, 2017 | Vancouver, Canada
WORLD CONFERENCE ON STDs, STIs & HIV/AIDS
allied
academies
G
lobally, an estimated 37 million people are living with
human immunodeficiency virus (HIV)-1. In the United
States, > 1.2 million people living with HIV and the most
worrisome issue is that among these people, it is estimated
that 13 % are unaware of their clinical status, leading to
unacceptably high HIV transmission rate. Joint United
Nations Programme on HIV/AIDS (UNAIDS) reported the
use of antiretroviral drugs (ARVs) has resulted in about 45%
drop in death caused by HIV/acquired immune deficiency
syndrome (HIV/AIDS). Still (2015 report), about 2.1 million
new infections have been reported worldwide, mainly due
to high HIV transmission rate and patient’s non-adherence
to ARVs. Therefore, the focus during formulating novel
effective therapeutics should not only be to improve the
quality of life of HIV/AIDS infected people but also to reduces
the possibility of infection transmission.
The cARVs has enhances the live expectancy of HIV patients,
which was once considered to be a uniformly fatal disease.
However, daily oral therapy is mandatory to achieve the
goal of a nondetectable plasma viral load (pVL) along with a
highly motivated, adherent patient. Therefore, cARV therapy
faces major challenges including adherence, a daily large
oral dose, with associated drug side effects, and economics.
Here, cARV nanomedicine could be a potential alternative.
Various surveys on HIV-infected patients reflects that
they are enthusiastic about long-acting parenteral
nanomedicines. Thus, researchers are actively developing
long-acting nanomedicines for HIV-1 prevention/treatment.
To improve patient lifestyle and control the epidemic, HIV/
AIDS therapeutics research goals for developing new ARV
drugs are: potent, non-toxic or with few side effects, small
dosages to ensure better adherence, and long-term viral
load maintenance. High HIV/AIDS prevalence in areas
of underdeveloped and developing countries, therefore
cARV should be inexpensive as well as readily accessible to
resource-limited countries.
To fulfill above prerequisite, we are formulating cARVs
encapsulated polymeric nanoparticle (NPs) as nanodrug
delivery system, that shows slow drug release and protects
drugs from systemic clearance. Therefore, we predict use of
cARV NPs will lead to monthly dosing, that potentially could
overcome the adherence burden in the HIV patient. We are
the first to report the use of PLGA encapsulated cARV drugs
(i.e. TAF+EVG and/ FTC) NPs for prevention/treatment of HIV
in a humanized mouse model.
Speaker Biography
Post doctoral researcher at Creighton university.
e:
SubhraMandal@creighton.eduCombination antiretroviral (cARV) loaded nanoparticles: A potential alternative future for HIV patients
Subhra Mandal
and
Christopher J. Destache
Creighton University School of Pharmacy & Health Professions, Omaha, NE